Parathyroid Hormone Global Market Types and Applications, Drivers, Ongoing Trends, Future Demand, Challenges, Top Companies And Forecast 2024-2033

The parathyroid hormone market size has grown steadily in recent years. It will grow from $2.35 billion in 2023 to $2.43 billion in 2024 at a compound annual growth rate (CAGR) of 3.5%. The growth in the historic period can be attributed to rising prevalence of chronic kidney disease, increasing awareness of parathyroid hormone-related disorders, growing demand for parathyroid hormone analogs, increased government funding for parathyroid hormone research, rising disposable incomes.

The parathyroid hormone market size is expected to see steadily grown in the next few years. It will grow to $3.5 billion in 2028 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to growing geriatric population, expansion of private healthcare sectors, emerging indications, precision medicine, growing awareness of bone health, expanding healthcare access. Major trends in the forecast period include advances in parathyroid hormone testing, advances in drug delivery, combination therapies, digital health integration, sustainability and green initiatives.

Market Overview -
Parathyroid hormone refers to a substance produced by the parathyroid gland that aids in the body's storage and utilization of calcium. High blood calcium levels are a result of parathyroid hormone levels that are greater than usual and could be a disease indicator. It is also known as PTH, parathyrin, and parathormone.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=3427&type=smp

Elevated Prevalence Of Osteoporosis Sparks Growth In The Parathyroid Hormone Market
The rise in the prevalence of osteoporosis is expected to drive the market for parathyroid hormones. Osteoporosis is a disease characterized by low bone mass and deterioration of bone tissue, which further leads to an increased risk of fracture. According to the International Osteoporosis Foundation, osteoporosis affects approximately 1.4 million Canadians, mainly postmenopausal women and the elderly. The parathyroid hormone, which is naturally produced by the body for regulating calcium levels, is used to reduce the risk of bone fracture in people with osteoporosis and is administered as a daily subcutaneous injection. The increase in osteoporosis is therefore expected to contribute to the growth of the parathyroid hormone market.

Competitive Landscape -
Major companies operating in the parathyroid hormone market include Pfizer Inc., Eli Lilly and Company, Radius Health Inc., Shire plc, Ascendis Pharma, Entera Bio Ltd., Extend Biosciences Inc., Gedeon Richter Plc., Abbott Laboratories, Amgen Inc., Merck & Co. Inc., Novartis AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., Alcon Laboratories Inc., Bayer Healthcare, Becton Dickinson and Company, Ethicon Inc., Genentech Inc., Medtronic Inc., Mylan Laboratories, Novo Nordisk, Smith & Nephew plc, Stryker Corporation, Zimmer Biomet Holdings Inc.

Biosimilar Development In The Parathyroid Hormone Market Is Enhancing Affordability And Treatment Standards
Companies in the parathyroid hormone market are focusing on developing biosimilars of parathyroid-based drugs. A biosimilar is a biological product that is developed to be similar to an already FDA-approved biologic, known as the reference product. Biosimilars potentially offer consumers the opportunity to reduce their healthcare costs without compromising on treatment standards, which is why parathyroid hormone manufacturing companies are investing in them. For instance, in January 2021, Theramex a UK-based pharmaceutical company launched Livogiva. Teriparatide, the only bone anabolic medication for osteoporosis, is now available in a novel form called Livogiva, a pre-filled pen that makes it simple for patients who are at high risk of osteoporosis to take. Livogiva is recommended for postmenopausal women with osteoporosis who are at higher risk of fracture .

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report

Key Segments -
The parathyroid hormone market covered in this report is segmented -
1) By Disease Type: Hypocalcaemia, Hypoparathyroidism
2) By Product Type: Recombinant Parathtyoid Hormone, Parathyroid Hormone Analogues
3) By End-User: Hospitals, Clinics, Othe End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.